Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2

Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2

Background Cancer immunotherapy with monoclonal antibodies and chimeric antigen receptor (CAR) T cell therapies can benefit from selection of new targets with high levels of tumor specificity and from early assessments of efficacy and safety to derisk potential therapies.Methods Employing mass spect...

Full description

Bibliographic Details
Main Authors: Debra H Josephs, Giulia Pellizzari, Olivier Martinez, Silvia Crescioli, Robert Page, Ashley Di Meo, Silvia Mele, Giulia Chiaruttini, Jan Hoinka, Ihor Batruch, Ioannis Prassas, Melanie Grandits, Jacobo López-Abente, Eva Bugallo-Blanco, Malcolm Ward, Heather J Bax, Elise French, Anthony Cheung, Sara Lombardi, Mariangela Figini, Katie E Lacy, Eleftherios P Diamandis
Format: Article
Language:English
Published: BMJ Publishing Group 2021-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/6/e002140.full

Internet

https://jitc.bmj.com/content/9/6/e002140.full

Similar Items